---
title: "SSY GROUP: Benzenesulfonic Acid Amlodipine Tablets Obtained Drug Production Registration Approval"
description: "According to the Zhitong Finance APP, SSY GROUP announced that it has obtained the drug production registration approval from the National Medical Products Administration of China for Amlodipine Besyl"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/261547438.md"
published_at: "2025-10-17T04:10:05.000Z"
---

# SSY GROUP: Benzenesulfonic Acid Amlodipine Tablets Obtained Drug Production Registration Approval

> According to the Zhitong Finance APP, SSY GROUP announced that it has obtained the drug production registration approval from the National Medical Products Administration of China for Amlodipine Besylate Tablets (5mg and 2.5mg), which are classified as Category 4 chemical drugs and are considered to have passed the consistency evaluation. Amlodipine Besylate Tablets are primarily used for the treatment of hypertension, chronic stable angina, and vasospastic angina, and can be used alone or in combination with other medications

According to the announcement from Stone Four Pharmaceutical Group (02005), the group has obtained the drug production registration approval from the National Medical Products Administration of China for Amlodipine Besylate Tablets (5mg and 2.5mg), which are classified as Category 4 chemical drugs and are considered to have passed the consistency evaluation.

Amlodipine Besylate Tablets are primarily used for the treatment of hypertension, chronic stable angina, and vasospastic angina, and can be used alone or in combination with other medications

### Related Stocks

- [02005.HK - SSY GROUP](https://longbridge.com/en/quote/02005.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| SSY Group Wins Chinese Government Bid to Supply Medicines to Healthcare Facilities | SSY Group Wins Chinese Government Bid to Supply Medicines to Healthcare Facilities | [Link](https://longbridge.com/en/news/263006264.md) |
| SSY Group Ltd. Secures Chinese Regulatory Approval for Levamlodipine Besilate Tablets | SSY Group Ltd. has received approval from China's National Medical Products Administration for Levamlodipine Besilate Ta | [Link](https://longbridge.com/en/news/261547083.md) |
| Towa Pharmaceutical (TSE:4553) Margin Firmness Reinforces Defensive Earnings Narrative In Q3 2026 | Towa Pharmaceutical (TSE:4553) reported solid Q3 2026 results with revenue of ¥73.6b and net income of ¥8.9b, reflecting | [Link](https://longbridge.com/en/news/275991027.md) |
| SSY Group Wins China Approval for New Hypertension Combination Drug | SSY Group Limited has received approval from China's National Medical Products Administration for its Perindopril Argini | [Link](https://longbridge.com/en/news/271492775.md) |
| SSY Group Receives Approval for 2ml Composite Potassium Hydrogen Phosphate Injection in China | SSY Group Ltd. has received approval from China's National Medical Products Administration for its 2ml Composite Potassi | [Link](https://longbridge.com/en/news/273678089.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.